Chemoimmunotherapy Drugs with Antiviral Activity to Treat Patients with Lung Cancer and COVID-19; a Narrative Review
Men's Health Journal,
Vol. 7 No. 1 (2023),
22 January 2023
,
Page e1
https://doi.org/10.22037/mhj.v7i1.40897
Abstract
Every year lung cancer is a cause of high morbidity and mortality in the human population. However, since 31 December 2019, the coronavirus disease 2019 [COVID-19] had importantly affected various degrees of pulmonary regions. Therefore, patients with lung cancer must be the priority group for COVID-19 prevention, treatment, and vaccination during the COVID-19 pandemic. Until now, clinicians and patients know that most individuals with respiratory distress and/or those with a weakened immune system are more susceptible to COVID-19, however, the associations with lung cancer remain unclear. Here, we present the combination of common chemotherapeutic drugs with a historical antiviral activity that may be too immunosuppressive to eliminate COVID-19-infected cells in patients with lung cancer. This review will help understand the preferred chemoimmunotherapy drugs for severe forms of COVID-19 [SARS-CoV-2] in these patients.
- COVID-19
- antiviral activity
- chemotherapeutic drugs
- lung cancer
How to Cite
References
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol 2020;31(7):894-901. https://doi.org/10.1016/j.annonc.2020.03.296.
Hartenian E, Nandakumar D, Lari A, Ly M, Tucker JM, Glaunsinger BA. The molecular virology of coronaviruses. J Biol Chem 2020;11;295(37):12910-12934. https://doi.org/10.1074/jbc.REV120.013930.
Renu K, Prasanna PL, Gopalakrishnan AV. Coronaviruses pathogenesis, comorbidities and multi-organ damage-A review. Life Sci 2020;255:117839. https://doi.org/10.1016/j.lfs.2020.117839.
Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-337. https://doi.org/10.1016/S1470-2045(20)30096-6.
Xu Y, Liu HS, Hu K, Wang M. Clinical management of lung cancer patients during the outbreak of 2019 novel coronavirus disease (COVID-19). Chin J Lung Cancer 2020;23(3):136-141. https://doi.org/10.3779/j.issn.1009-3419.2020.03.02.
Addeo A, Friedlaender A. Cancer and COVID-19: Unmasking their ties. Cancer Treat Rev 2020;88:102041. https://doi.org/10.1016/j.ctrv.2020.102041.
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov 2020;10:783-791. https://doi.org/10.1158/2159-8290.CD-20-0422.
Magro C, Justin Mulvey J, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020;220:1-13. https://doi.org/10.1016/j.trsl.2020.04.007.
Luo J, Rizvi H, Preeshagul IR, et al. COVID-19 in patients with lung cancer. Ann Oncol 2020;31(10):1386-1396. https://doi.org/10.1016/j.annonc.2020.06.007.
Yousefi B, Valizadeh S, Ghaffari H, Vahedi A, Karbalaei M, Eslami M. A global treatments for coronaviruses including COVID-19. J Cell Physiol 2020;235(12):9133-9142. https://doi.org/10.1002/jcp.29785.
Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID 19: who won and who lost? Ortolani and Pastorello Clin Mol Allergy 2020;18:17. https://doi.org/10.1186/s12948-020-00132-7.
Takami A. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19. Int J Hematol 2020;112(1):122-124. https://doi.org/10.1007/s12185-020-02888-9.
Loscocco GG. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID 19. Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19. Int J Hematol 2020;112(1):125-126. https://doi.org/10.1007/s12185-020-02895-w.
Al-Motawa MS, Abbas H, Wijten P, de la Fuente A, Xue M, Rabbani N, et al. Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity for Repurposed Chemotherapy of COVID-19 Infection. Front Pharmacol 2020;11:585408. https://doi.org/10.3389/fphar.2020.585408.
Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 2020;12:269-73. https://doi.org/10.2217/imt-2020-0067.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression (letter). Lancet 2020;395:1033-4. https://doi.org/10.1016/S0140-6736[20]30628-0.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-8. https://doi.org/10.1007/s00134-020-05991-x.
Bonomi M, Maltese M, Brighenti M, Muri M, Passalacqua R. Tocilizumab for COVID-19 Pneumonia in a Patient With None Small-cell Lung Cancer Treated With Chemoimmunotherapy. Clin Lung Cancer 2021;22(1):e67-9. https://doi.org/10.1016/j.cllc.2020.08.002.
Ascierto PA. SITC Statement on anti-IL-6/IL-6R for COVID-19 - Society for Immunotherapy of Cancer (SITC). 2020. Available: https://www.sitcancer.org/research/covid-19-resources/il-6-editorial.
Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020;19:102568. https://doi.org/10.1016/j.autrev.2020.102568.
Scott LJ. Tocilizumab: A Review in Rheumatoid Arthritis. Drugs 2017;77(17):1865–1879. https://doi.org/10.1007/s40265-017-0829-7.
Rezonja R, Knez L, Cufer T, Mrha A. Oral treatment with etoposide in small cell lung cancer-dilemmas and solutions. Radiol Oncol 2013;47(1):1-13. https://doi.org/10.2478/raon-2013-0008.
Aoyagi T, Sato Y, Toyama M, Oshima K, Kawakami K, Kaku M. Etoposide and corticosteroid combination therapy improves acute respiratory distress syndrome in mice. Shock 2019;52(1):83–91. https://doi.org/10.1097/SHK.0000000000 00123-1.
Shin HJ, Kim C, Cho S. Gemcitabine and nucleostide synthesis inhibitors are broad-spectrum antiviral drugs that activate innate immunity. Viruses 2018;10(4):211. https://doi.org/10.3390/v10040211.
Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection. Antimicrob. Agents Chemother 2014;58:4885-4893. https://doi.org/10.1128/AAC.03036-14.
Zhang YN, Zhang QY, Li XD, Xiong J, Xiao SQ, Wang Z, et al. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture. Emerg Microbes Infect 2020;9(1):1170–1173. https://doi.org/10.1080/22221751.2020.1772676.
Lee K, Kim DE, Jang KS, Kim SJ, Cho S, Kim C. Gemcitabine, a broadspectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion. Oncotarget 2017;8:115315-115325. https://doi.org/10.18632/oncotarget.23258.
Zheng Z, Groaz E, Snoeck R, Jonghe SD, Herdewijn P, Andrei G. Influence of 4′-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV 2. ACS Med Chem Lett 2021;12(1):88–92. https://doi.org/10.1021/acsmedchemlett.0c00485.
Zhang CC, Li CG, Wang YF, Xu LH, He XH, Zeng QZ, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis 2019;24(3-4):312-325. https://doi.org/10.1007/s10495-019-01515-1.
Mazieres J, Kowalski D, Luf A, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol 2020;38(3):271-280. https://doi.org/10.1200/JCO.19.01348.
Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994;5(Suppl:6):S3-6.
Grant RC, Rotstein C, Liu G, Forbes L, Vu K, Lee R, et al. Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada. Support Care Cancer 2020;28(10):5031-5036. https://doi.org/10.1007/s00520-020-05588-6.
Abdolahi N, Kaheh E, Golsha R, et al. Letter to the editor: efficacy of different methods of combination regimen administrations including dexamethasone, intravenous immunoglobulin, and interferon-beta to treat critically ill COVID-19 patients: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:549. https://doi.org/10.1186/s13063-020-04499-5.
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020;324(13):1-11. https://doi.org/10.1001/jama.2020.17021.
Gurunathan S, Jeyaraj M, Kang MH, Kim JH. Melatonin Enhances Palladium-Nanoparticle-Induced Cytotoxicity and Apoptosis in Human Lung Epithelial Adenocarcinoma Cells A549 and H1229. Antioxidants (Basel) 2020;9(4):357. https://doi.org/10.3390/antiox9040357.
Ari F, Erkisa M, Buyukkoroglu G, Senel B, Yılmaz VT, Ulukaya E. Palladium nanoparticles selectively induce apoptosis in lung cancer cells through reactive oxygen species. J Cancer Sci Ther 2018;23-25. https://doi.org/10.4172/1948-5956-C8-145.
Haribabu J, Srividya S, Mahendiran D, Gayathri D, Venkatramu V, Bhuvanesh N, Karvembu R. Synthesis of Palladium[II] Complexes via Michael Addition: Antiproliferative Effects through ROS-Mediated Mitochondrial Apoptosis and Docking with SARS-CoV 2. Inorg Chem 2020;59:17109−17122. https://dx.doi.org/10.1021/acs.inorgchem.0c02373.
- Abstract Viewed: 121 times
- pdf Downloaded: 132 times